Consultation on CE-Marked Medical Devices ‘Could Mark Major Boost to Both Patients and MedTech Growth Aims’

Key Takeaways

• 90% of GB devices already CE‑marked.
• Indefinite recognition could eliminate regulatory duplication.
• Consultation runs until 10 April 2026.
• Proposals include EU MDR/IVDR alignment and reliance route.
• Expected to boost MedTech investment and patient access.

Summary

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has launched a consultation on granting indefinite recognition to CE‑marked medical devices in Great Britain. Around 90% of devices used in the UK already carry CE marks, and the proposals aim to extend current transitional arrangements, align GB timelines with the EU MDR/IVDR, and create an international reliance route for higher‑risk devices. Regulators and industry groups, including InnoScot Health, argue the move would simplify compliance, secure supply chains and support MedTech growth. The consultation closes on 10 April 2026.

Pulse Analysis

Post‑Brexit, the United Kingdom has operated under a parallel regulatory framework for medical devices, creating uncertainty for manufacturers and potential supply gaps for hospitals. CE marking, the European Union’s safety and performance label, still covers the vast majority of products on the British market, but the need to repeatedly certify under separate UK rules adds cost and delays. By seeking indefinite recognition of CE‑marked devices, the MHRA aims to harmonise standards, leveraging the existing EU certification infrastructure while preserving the UK’s ability to enforce its own safety requirements where necessary.

The consultation outlines three core proposals: extending the transitional period for devices certified under the old EU Medical Device Directive, granting perpetual acceptance of devices meeting EU MDR and IVDR criteria, and establishing an international reliance pathway for a limited set of higher‑risk devices. These measures would mitigate the risk of supply interruptions, streamline market entry for innovators, and reduce administrative burdens for Approved Bodies and UK Responsible Persons. Stakeholders such as InnoScot Health see the approach as a pragmatic bridge to a more integrated regulatory relationship with Europe, potentially unlocking cross‑border collaborations and accelerating the development of AI‑driven medical technologies.

If adopted, indefinite CE recognition could reshape the UK’s MedTech landscape. A clearer, unified pathway would likely attract foreign investment, encourage domestic R&D, and support the rollout of cutting‑edge therapies that rely on rapid regulatory approval. Moreover, aligning with EU standards may facilitate the export of UK‑originated devices to the broader European Economic Area, enhancing the sector’s global competitiveness. The consultation’s outcome will therefore be a bellwether for the UK’s strategic positioning in the fast‑evolving health‑technology market.